NYSE:AMAM
Ambrx Biopharma Inc. Stock News
$28.00
+0 (+0%)
At Close: Apr 29, 2024
3 Stocks to Buy That Are Up 200% or More in 2024
02:19pm, Friday, 23'rd Feb 2024
With stocks up 200%, you face a dilemma. While you don't want to fight momentum, you also don't want to buy into excessive exuberance and jump into a stock at its top, forced to hold until break-even
Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 20'th Feb 2024
Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year.
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
02:17pm, Tuesday, 09'th Jan 2024
J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
12:22pm, Monday, 08'th Jan 2024
Shares of engineered therapeutics specialist Ambrx Biopharma (NASDAQ: AMAM ) skyrocketed on Monday following a major announcement. Pharmaceutical and medical technology stalwart Johnson & Johnson (NYS
Cramer's Mad Dash: Ambrx Biopharma Inc.
10:43am, Monday, 08'th Jan 2024
CNBC's Jim Cramer delivers his daily Mad Dash.
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
09:09am, Monday, 08'th Jan 2024
The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.
The underdogs of 2023: Small-cap stocks that made it big
07:15am, Tuesday, 26'th Dec 2023
In recent years, most reports of assets surging by thousands of percents in relatively short periods come from the crypto market, where various cryptocurrencies – especially smaller altcoins and mem
Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data
11:23am, Tuesday, 24'th Oct 2023
Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology fo
Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data
06:50pm, Monday, 23'rd Oct 2023
Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. In order to see if ARX517 can be improved upon for
Why Shares of Ambrx Biopharma Soared This Week
07:47pm, Thursday, 21'st Sep 2023
The company, formerly based in the Cayman Islands, is moving to Delaware. It is expected to announce trial data next week regarding two of its lead therapies.
Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences
08:30am, Tuesday, 05'th Sep 2023
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx
Is Ambrx Biopharma (AMAM) Outperforming Other Medical Stocks This Year?
11:17am, Wednesday, 23'rd Aug 2023
Here is how Ambrx Biopharma Inc. Sponsored ADR (AMAM) and Sientra (SIEN) have performed compared to their sector so far this year.
Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
08:30am, Friday, 28'th Jul 2023
Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time clinical data regarding ARX517 will be presented at
Ambrx to Present at Multiple Upcoming Investor Meetings
09:01am, Tuesday, 30'th May 2023
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambr
Ambrx Biopharma: ARX788's Potential In Cancer Treatment Presents Promising Opportunity
12:46am, Saturday, 20'th May 2023
Ambrx Biopharma's stock value has surged due to positive preliminary data from cancer-targeting clinical trials of ARX788 and ARX517. With cash reserves increasing to $149.6 million in Q1 2023, Ambrx